Heterogeneity assessment of vaccine‐induced effects using point‐of‐care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2

Abstract

Introduction:Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic even after vaccination. We aimed to identify immunological heterogeneity over time in vaccinated healthcare workers using neutralization antibodies and neutralizing activity tests. Methods: Serum samples were collected from 214 healthcare workers before vaccination (pre) and on days 22, 90, and 180 after receiving the first dose of BNT162b2 vaccine (day 0). Neutralization antibody (NAb, SARS-CoV-2 S-RBD IgM/IgG) titers and two kinds of surrogate virus neutralization tests (sVNTs) were analyzed (UMIN000043851). Results:The NAb (SARS-CoV-2 S-RBD IgG) titer peaked on day 90 after vaccination (30,808.0 μg/ml ± 35,211; p < 0.0001) and declined on day 180 (11,678.0 μg/ ml ± 33,770.0; p < 0.0001). The neutralizing activity also peaked on day 90 and declined with larger individual differences than those of IgG titer on day 180 (88.9% ± 15.0%, 64.8% ± 23.7%, p < 0.0001). We also found that the results of POCT-sVNT (immunochromatography) were highly correlated with those of conventional sVNT (ELISA). Conclusions:Neutralizing activity is the gold standard for vaccine efficacy evaluation.Our results using conventional sVNT showed large individual differences in neutralizing activity reduction on day 180 (64.8% ± 23.7%), suggesting an association with the difference in vaccine efficacy. POCT-sVNT is rapid and user-friendly; it might be used for triage in homes, isolation facilities, and event venues without restrictions on the medical testing environment.

Time‐series transcriptome analysis of peripheral blood mononuclear cells obtained from individuals who received the SARS‐CoV‐2 mRNA vaccine

“…In this study, we performed a transcriptomics analysis (RNA sequencing [RNA‐seq]) of PBMC samples from 214 healthcare workers before vaccination (T1) and on Days 22 (T2), 180 (T3), and 360 (T4) after receiving the first dose of BNT162b2 vaccine (UMIN000043851). For the integrated analysis, neutralization antibody (Nab) and surrogate virus neutralization tests (sVNTs) were performed 21 …”